肌少症对肝移植患者预后影响的研究进展

李宇轩; 刘文亚

doi:10.3969/j.issn.1001-5256.2021.06.052

肌少症对肝移植患者预后影响的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.06.052

李宇轩^1, ,,
刘文亚²

1.
新疆医科大学第一临床学院, 乌鲁木齐 830054
2.
新疆医科大学第一附属医院影像中心, 乌鲁木齐 830054

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：李宇轩负责拟定写作思路、搜集相关文献以及撰写原稿；刘文亚负责论文修改及最终定稿审查。

详细信息

作者简介:
李宇轩（1996—），男，主要从事骨骼肌肌肉系统研究

通信作者:
李宇轩，3117089643@qq.com

中图分类号: R617
计量
- 文章访问数: 419
- HTML全文浏览量: 142
- PDF下载量: 31
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-28
- 录用日期: 2020-11-17
- 出版日期: 2021-06-20

Research advances in the value of sarcopenia in the prognosis of patients after liver transplantation

Yuxuan LI^{1
, ,},
Wenya LIU²

1.
The First Clinical College of Xinjiang Medical University, Urumqi 830054, China
2.
Imaging Center of The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China

摘要

摘要: 肌少症常伴发于晚期肝癌等终末期肝病患者，这种并发症与肝移植围术期的病死率相关，而有限的肝脏资源要求传统评估体系进一步改善移植队列的生存率。通过对骨骼肌病理机制和诊治策略的汇总评价，可以看出骨骼肌作为一种有效预测患者生存的身体成分参数，配合肝功能评估量表可优化移植队列顺序和手术效益。其相关死亡的具体机制并不清晰，诊断指标逐渐精简，尚无可以逆转病死率的治疗策略。根据现有文献，肌少症是确定肝移植候选人的重要参数之一。
- 肌肉减少症 /
- 肝移植 /
- 预后
Abstract: Sarcopenia is often observed in patients with end-stage liver disease such as advanced liver cancer. This complication is associated with mortality rate in the perioperative period of liver transplantation, and limited liver resources require traditional evaluation systems to further improve the survival rate of the transplant cohort. Summarization and evaluation of skeletal muscular pathology and diagnosis and treatment strategies show that as a body composition parameter that can effectively predict the survival of patients, skeletal muscle can help to optimize the sequence of transplantation cohorts and surgical benefits in combination with liver function assessment scale. The specific mechanism of related death remains unclear, the diagnostic indicators are gradually streamlined, and there is no treatment strategy that can reverse the mortality rate. Based on the existing literature, sarcopenia is one of the important parameters for determining candidates for liver transplantation.
- Sarcopenia /
- Liver Transplantation /
- Prognosis

HTML全文

参考文献(38)

[1]	VURAL A, ATTAWAY A, WELCH N, et al. Skeletal muscle loss phenotype in cirrhosis: A nationwide analysis of hospitalized patients[J]. Clin Nutr, 2020, 39(12): 3711-3720. DOI: 10.1016/j.clnu.2020.03.032.
[2]	HAMAGUCHI Y, KAIDO T, OKUMURA S, et al. Proposal for new selection criteria considering pre-transplant muscularity and visceral adiposity in living donor liver transplantation[J]. J Cachexia Sarcopenia Muscle, 2018, 9(2): 246-254. DOI: 10.1002/jcsm.12276.
[3]	TUTTLE C, THANG L, MAIER AB. Markers of inflammation and their association with muscle strength and mass: A systematic review and meta-analysis[J]. Ageing Res Rev, 2020, 64: 101185. DOI: 10.1016/j.arr.2020.101185.
[4]	LIU X, HOU L, XIA X, et al. Prevalence of sarcopenia in multi ethnics adults and the association with cognitive impairment: Findings from West-China health and aging trend study[J]. BMC Geriatr, 2020, 20(1): 63. DOI: 10.1186/s12877-020-1468-5.
[5]	BEYER I, METS T, BAUTMANS I. Chronic low-grade inflammation and age-related sarcopenia[J]. Curr Opin Clin Nutr Metab Care, 2012, 15(1): 12-22. DOI: 10.1097/MCO.0b013e32834dd297.
[6]	DALLE S, ROSSMEISLOVA L, KOPPO K. The role of inflammation in age-related sarcopenia[J]. Front Physiol, 2017, 8: 1045. DOI: 10.3389/fphys.2017.01045.
[7]	PAPADOPOULOU SK. Sarcopenia: A contemporary health problem among older adult populations[J]. Nutrients, 2020, 12(5): 1293. DOI: 10.3390/nu12051293.
[8]	DUARTE-ROJO A, RUIZ-MARGÁIN A, MONTAÑO-LOZA AJ, et al. Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list[J]. Liver Transpl, 2018, 24(1): 122-139. DOI: 10.1002/lt.24958.
[9]	HAN F. Study on the correlation between muscle loss and nutritional risk in patients with liver cirrhosis or hepatocellular carcinoma[D]. Tianjin: Tianjin Medical University, 2019. 韩芳. 肝硬化及肝癌肌肉减少与营养风险相关性研究[D]. 天津: 天津医科大学, 2019.
[10]	KAPPUS MR, WEGERMANN K, BOZDOGAN E, et al. Use of skeletal muscle index as a predictor of wait-list mortality in patients with end-stage liver disease[J]. Liver Transpl, 2020, 26(9): 1090-1099. DOI: 10.1002/lt.25802.
[11]	PATERNOSTRO R, LAMPICHLER K, BARDACH C, et al. The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis[J]. Liver Int, 2019, 39(12): 2374-2385. DOI: 10.1111/liv.14217.
[12]	PONTI F, SANTORO A, MERCATELLI D, et al. Aging and imaging assessment of body composition: From fat to facts[J]. Front Endocrinol (Lausanne), 2019, 10: 861. DOI: 10.3389/fendo.2019.00861.
[13]	WANG X, WANG PJ, XIONG T, et al. Application of MRI in assessing fat infiltration of thigh muscles in progressive muscular dystrophy[J]. J Prac Radiol, 2019, 35(1): 81-84, 93. DOI: 10.3969/j.issn.1002-1671.2019.01.020. 王霞, 王鹏娟, 熊婷, 等. MRI对进行性肌营养不良大腿肌肉脂肪浸润评估的应用研究[J]. 实用放射学杂志, 2019, 35(1): 81-84, 93. DOI: 10.3969/j.issn.1002-1671.2019.01.020.
[14]	GRIMM A, MEYER H, NICKEL MD, et al. Repeatability of Dixon magnetic resonance imaging and magnetic resonance spectroscopy for quantitative muscle fat assessments in the thigh[J]. J Cachexia Sarcopenia Muscle, 2018, 9(6): 1093-1100. DOI: 10.1002/jcsm.12343.
[15]	KHAN AI, REITER DA, SEKHAR A, et al. MRI quantitation of abdominal skeletal muscle correlates with CT-based analysis: implications for sarcopenia measurement[J]. Appl Physiol Nutr Metab, 2019, 44(8): 814-819. DOI: 10.1139/apnm-2018-0473.
[16]	LEMOS T, GALLAGHER D. Current body composition measurement techniques[J]. Curr Opin Endocrinol Diabetes Obes, 2017, 24(5): 310-314. DOI: 10.1097/MED.0000000000000360.
[17]	GOLSE N, BUCUR PO, CIACIO O, et al. A new definition of sarcopenia in patients with cirrhosis undergoing liver transplantation[J]. Liver Transpl, 2017, 23(2): 143-154. DOI: 10.1002/lt.24671.
[18]	WILSON JP, STRAUSS BJ, FAN B, et al. Improved 4-compartment body-composition model for a clinically accessible measure of total body protein[J]. Am J Clin Nutr, 2013, 97(3): 497-504. DOI: 10.3945/ajcn.112.048074.
[19]	KAIDO T, TAMAI Y, HAMAGUCHI Y, et al. Effects of pretransplant sarcopenia and sequential changes in sarcopenic parameters after living donor liver transplantation[J]. Nutrition, 2017, 33: 195-198. DOI: 10.1016/j.nut.2016.07.002.
[20]	FUJIMOTO K, INAGE K, EGUCHI Y, et al. Dual-energy X-ray absorptiometry and bioelectrical impedance analysis are beneficial tools for measuring the trunk muscle mass of patients with low back pain[J]. Spine Surg Relat Res, 2019, 3(4): 335-341. DOI: 10.22603/ssrr.2018-0040.
[21]	WINGO BC, BARRY VG, ELLIS AC, et al. Comparison of segmental body composition estimated by bioelectrical impedance analysis and dual-energy X-ray absorptiometry[J]. Clin Nutr ESPEN, 2018, 28: 141-147. DOI: 10.1016/j.clnesp.2018.08.013.
[22]	AK_IN S, MUCUK S, ÖZTVRK A, et al. Muscle function-dependent sarcopenia and cut-off values of possible predictors in community-dwelling Turkish elderly: Calf circumference, midarm muscle circumference and walking speed[J]. Eur J Clin Nutr, 2015, 69(10): 1087-1090. DOI: 10.1038/ejcn.2015.42.
[23]	BOHANNON RW. Grip strength: An indispensable biomarker for older adults[J]. Clin Interv Aging, 2019, 14: 1681-1691. DOI: 10.2147/CIA.S194543.
[24]	ITOH S, YOSHIZUMI T, SAKATA K, et al. Slow gait speed is a risk factor for complications after hepatic resection[J]. J Gastrointest Surg, 2019, 23(9): 1810-1816. DOI: 10.1007/s11605-018-3993-5.
[25]	GONZÁLEZ CORREA CH, MARULANDA MEJÍA F, CASTAÑO GONZÁLEZ PA, et al. Bioelectrical impedance analysis and dual X-ray absorptiometry agreement for skeletal muscle mass index evaluation in sarcopenia diagnosis[J]. Physiol Meas, 2020, 41(6): 064005. DOI: 10.1088/1361-6579/ab8e5f.
[26]	ZAMBRANO DN, XIAO J, PRADO CM, et al. Patient-Generated Subjective Global Assessment and Computed Tomography in the assessment of malnutrition and sarcopenia in patients with cirrhosis: Is there any association?[J]. Clin Nutr, 2020, 39(5): 1535-1540. DOI: 10.1016/j.clnu.2019.06.018.
[27]	GHARAGOZLIAN S, MALA T, BREKKE HK, et al. Nutritional status, sarcopenia, gastrointestinal symptoms and quality of life after gastrectomy for cancer-A cross-sectional pilot study[J]. Clin Nutr ESPEN, 2020, 37: 195-201. DOI: 10.1016/j.clnesp.2020.03.001.
[28]	WEI CL. The role of L3 skeletal muscle mass index in gasstric cancer patients nutritional risk evaluation and prognosis evaluation[D]. Nanning: Guangxi Medical University, 2015. 韦朝联. L3骨骼肌质量指数对胃癌患者营养风险评估及预后影响的研究[D]. 南宁: 广西医科大学, 2015.
[29]	SHOREIBAH MG, MAHMOUD K, ABOUELDAHAB NA, et al. Psoas muscle density in combination with model for end-stage liver disease score can improve survival predictability in transjugular intrahepatic portosystemic shunts[J]. J Vasc Interv Radiol, 2019, 30(2): 154-161. DOI: 10.1016/j.jvir.2018.10.006.
[30]	ROMAGNA ES, APPEL-DA-SILVA MC, SUWA E, et al. Muscle depletion in cirrhotic patients assessed using computed tomography: A cross-sectional study[J]. Sao Paulo Med J, 2020, 138(2): 152-157. DOI: 10.1590/1516-3180.2019.0436.R1.19122019.
[31]	TIAN H, ZHOU D, YE C, et al. Effect of saropenia on clinical prognosis of gastric cancer patients: A prospective cohort study[J]. Paren And Ent Nutr, 2018, 25(3): 166-170, 175. DOI: 10.16151/j.1007-810x.2018.03.010. 田浩, 周达, 叶晨, 等. 术前肌肉减少症对胃癌病人临床预后的影响: 一项前瞻性队列研究[J]. 肠外与肠内营养, 2018, 25(3): 166-170, 175. DOI: 10.16151/j.1007-810x.2018.03.010.
[32]	RECIO-BOILES A, GALEAS JN, GOLDWASSER B, et al. Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT)[J]. Support Care Cancer, 2018, 26(7): 2353-2359. DOI: 10.1007/s00520-018-4051-2.
[33]	DING H, SUN JT, LI JJ, et al. The value of sarcopenia in assessing the operational risk and prognosis of rectal cancer patients[J]. J Prac Radiol, 2018, 35(3): 473-476. 丁晖, 孙精涛, 李军军, 等. 肌少症在评估直肠癌患者手术风险及预后中的价值[J]. 实用放射学杂志, 2018, 35(3): 473-476.
[34]	KIM G, KANG SH, KIM MY, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis[J]. PLoS One, 2017, 12(10): e0186990. DOI: 10.1371/journal.pone.0186990.
[35]	LIU J, HUANG H. Pathogenesis of sarcopenia in liver cirrhosis and current status of its diagnosis and treatment[J]. J Clin Hepatol, 2020, 36(4): 895-899. DOI: 10.3969/j.issn.1001-5256.2020.04.041. 刘嘉, 黄华. 肝硬化肌肉减少症的发病机制及诊治现状[J]. 临床肝胆病杂志, 2020, 36(4): 895-899. DOI: 10.3969/j.issn.1001-5256.2020.04.041.
[36]	CRUZ-JENTOFT AJ, BAEYENS JP, BAUER JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on sarcopenia in older people[J]. Age Ageing, 2010, 39(4): 412-423. DOI: 10.1093/ageing/afq034.
[37]	RUS GE, PORTER J, BRUNTON A, et al. Nutrition interventions implemented in hospital to lower risk of sarcopenia in older adults: A systematic review of randomised controlled trials[J]. Nutr Diet, 2020, 77(1): 90-102. DOI: 10.1111/1747-0080.12608.
[38]	PRAKTIKNJO M, CLEES C, PIGLIACELLI A, et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt[J]. Clin Transl Gastroenterol, 2019, 10(4): e00025. DOI: 10.14309/ctg.0000000000000025.